Navigation Links
Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer -

LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- Response Genetics, Inc. today announced that positive Phase III clinical data published in the July 1 issue of the Journal of Clinical Oncology suggests that low expression of the biomarker Excision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsies with advanced non-small cell lung cancer (NSCLC) predicts for sensitivity to cisplatin-based chemotherapy. ERCC-1 is an enzyme involved in repair of DNA strand breaks such as those caused by cisplatin. The analysis of ERCC-1 levels in this study was conducted by Response Genetics using its RGI-1 technology. Data from previous studies published by the Company in Clinical Cancer Research 2002 and Annals of Oncology 2006 showing that ERCC-1 was associated with tumor sensitivity to cisplatin formed the basis for the present study. This is the first prospective study using a biomarker to predict chemotherapy response in lung cancer. These findings support the use of measurement of ERCC-1 for individualizing therapies for lung cancer patients.

The Phase III multicenter, randomized study was designed to determine the overall response rate (complete plus partial responses) of patients with stage IIIb or IV NSCLC to cisplatin-based therapy by determining levels of the biomarker ERCC-1 mRNA in their paraffin-embedded tissue biopsy before administering treatment. Patients were prospectively assigned treatment to a cisplatin or non-cisplatin-based chemotherapy depending on whether the ERCC-1 gene expression in their tumor sample was above or below a specific threshold. Patients were assigned to one of two arms in this trial. The control arm consisted of all patients receiving cisplatin-based therapy. Patients in the "genotypic" arm were separated by levels of ERCC-1. Cisplatin-based therapy (docetaxel/cisplatin) was assigned to patients with low
'"/>




Page: 1 2 3 4

Related medicine technology :

1. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
5. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
8. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
9. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
10. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
11. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
Post Your Comments:
(Date:5/15/2008)... France, May 15 /- Cerenis,Therapeuti...ompany,developing HDL-related compounds for the tr...today announced that it has completed a Phase I,cl...d product candidates.,CER-002 is a peroxisome prol...agonist in development for the treatment of cardio...
(Date:5/15/2008)... CenterWatch, a publishing and,information service...l,trials, finds that investigative sites are requi...) systems. More than 75% of respondents to a recen...trained on three or more,EDC systems. In addition,...eir EDC training had improved., State of the Clin...
(Date:5/15/2008)...wire-FirstCall/ -- Novavax, Inc. (Nasdaq:,NVAX) to...the Phase I/IIa,study of its pandemic influenza va...cts. Favorable interim results from the first phas...70 healthy adult volunteers, were,reported in Dece... vaccine,is well tolerated and immunogenic at the ...
(Date:5/15/2008)... Plan Positions Blue Cross Blue Shield of Mic...rt from HealthLeaders-Inter...ealthLeaders-InterStudy, the,leading provider of m...he,economy continues to stagnate in Michigan, Blue...uipped of all of its competitors to weather the,ec...
Breaking Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 1Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 5Phlo Reports Sharp Revenue Increase 3441 1Phlo Reports Sharp Revenue Increase 3441 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 1Cancer Cure Coalition Proposes Major Changes at the FDA 1404 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 1Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 2Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 4
(Date:5/16/2008)... HAE: TSX, MONTREAL...ation,(TSX:HAE), a specialty bio-therapeutics comp...rcialization, announced today that its Chairman of...li, will present at the,upcoming Rodman & Renshaw ..., May 20, 2008 in the Zephyr Room at Le Meridien B...
(Date:5/16/2008)... SAO PAULO, Brazil, May 16 /PRNewswire-FirstCall/ ...rs: TEMP3.SA; Bloomberg: TEMP3 BZ), a leading,prov... benefit plans and,specialized assistance services...r of 2008. The operating and financial information...d, is presented in Brazilian Reais and in,accordan...
(Date:5/15/2008)...PHILADELPHIA) Combining natural organic atoms wit...ute have developed a new type of enzyme inhibitor ...ys a key role in cancer development. , Based on...es the way for developing new ways to treat cancer...leads to uncontrolled tumor growth. , Details of...
(Date:5/15/2008)... HARBIN, China, May 15 /Xinhua-PRNewswire-FirstCal...tin Board: CYXI) ("China Yingxia" or "the,Company"...y engaged in the,development, manufacture and dist...plements, and personal care products in the People...inancial results for the first,quarter ended March...
Breaking Medicine News(10 mins):Health News:Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9
...Daniel Stetson have reported in the Journal Immuni...rent mechanism to viral DNA infection. // Viruses...to DNA and RNA viruses and researchers have found ...ognisation of these viral products in the host is ...
...ngcheng Zhang from Whitehead Institute for Biomedi... of growth factors// which enriches and increases ...it could be injected into the recipient. Stem ce... stem cells required for a therapy is very high an...
...om Motor Neurone Disease (MND), a fatal nerve dise...a simple ventilator and facemask//. Patients suff...it from the new technique called non-invasive vent...e with MND who suffer from weakness of the respira...
...ffective as it is claimed to be. Therefore purchas...t// is viewed as nothing more than a waste of mone... on the above finding, several recommendations hav...treatment of coughs by the American College of Che...
Other Medicine News:
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: